Vera reaction to competitor IgAN update ‘overdone,’ says Goldman Sachs
Goldman Sachs notes that Vera Therapeutics (VERA) shares are down 18% and underperforming the biotech group today following earnings results ...
Hosted on MSN17d
Vera started at buy by Goldman Sachs, atacicept potential cited
Goldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock. The investment ...
ETF Daily News15d
Vera Therapeutics (NASDAQ:VERA) Research Coverage Started at The Goldman Sachs Group
The Goldman Sachs Group started coverage on shares of Vera Therapeutics (NASDAQ:VERA – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat reports. The firm issued ...
Business Insider18d
Vera Therapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent pullback, the firm sees Vera shares as at “an ...